Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables (2018 - 2026)

Denali Therapeutics has reported Receivables over the past 8 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Receivables changed 0.28% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, changed 0.28% year-over-year, with the annual reading at $2.2 million for FY2025, 0.28% changed from the prior year.
  • Receivables was $2.2 million for Q4 2025 at Denali Therapeutics, up from $1.9 million in the prior quarter.
  • Over five years, Receivables peaked at $16.6 million in Q2 2021 and troughed at $357000.0 in Q2 2022.
  • The 5-year median for Receivables is $2.0 million (2023), against an average of $3.1 million.
  • Year-over-year, Receivables surged 5422.33% in 2021 and then tumbled 97.85% in 2022.
  • A 5-year view of Receivables shows it stood at $1.2 million in 2021, then skyrocketed by 657.1% to $9.3 million in 2022, then tumbled by 70.91% to $2.7 million in 2023, then fell by 19.59% to $2.2 million in 2024, then increased by 0.28% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Receivables are $2.2 million (Q4 2025), $1.9 million (Q3 2025), and $1.4 million (Q2 2025).